Shire rebuffs AbbVie

Share this article:

Shire has turned AbbVie down yet again. An acquisition would benefit Chicago's AbbVie in two key ways. First, a successful acquisition would give the Illinois firm a favorable tax address if it declares Ireland its home. Second, the acquisition would give AbbVie a foothold in the rare-disease space in which Shire has established itself. AbbVie offered to buy Shire for $46.5 billion.

Shire made a case for its independence in a presentation Monday, in which the company said it is poised to bring in $10 billion in product sales by 2020. The company anticipates that in-line product sales will make up 70% of that projection, and the remaining $3 billion, or 30%, will come from existing pipeline products.

Shire told investors that near-term expectations hover around the $6.5 billion sales mark for next year.

Cenkos Securities analyst Navid Malik tells Bloomberg Shire's 2020 forecast  is “very achievable” and the New York Times notes that Shire has been shaping itself for this very moment through efforts including its $4.2 billion ViroPharma acquisition in November.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.